HomeCompareLPUSF vs ABBV

LPUSF vs ABBV: Dividend Comparison 2026

LPUSF yields 4.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $64.0K in total portfolio value
10 years
LPUSF
LPUSF
● Live price
4.14%
Share price
$3.31
Annual div
$0.14
5Y div CAGR
16.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.3K
Annual income
$3,467.67
Full LPUSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LPUSF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPUSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPUSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPUSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPUSF
Annual income on $10K today (after 15% tax)
$351.81/yr
After 10yr DRIP, annual income (after tax)
$2,947.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,108.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPUSF + ABBV for your $10,000?

LPUSF: 50%ABBV: 50%
100% ABBV50/50100% LPUSF
Portfolio after 10yr
$70.3K
Annual income
$14,119.72/yr
Blended yield
20.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LPUSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.8
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPUSF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPUSFABBV
Forward yield4.14%3.06%
Annual dividend / share$0.14$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.8%40.6%
Portfolio after 10y$38.3K$102.3K
Annual income after 10y$3,467.67$24,771.77
Total dividends collected$15.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: LPUSF vs ABBV ($10,000, DRIP)

YearLPUSF PortfolioLPUSF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,183$483.43$11,550$430.00$367.00ABBV
2$12,556$590.16$13,472$627.96$916.00ABBV
3$14,159$723.30$15,906$926.08$1.7KABBV
4$16,040$890.30$19,071$1,382.55$3.0KABBV
5$18,264$1,100.98$23,302$2,095.81$5.0KABBV
6$20,911$1,368.43$29,150$3,237.93$8.2KABBV
7$24,085$1,710.25$37,536$5,121.41$13.5KABBV
8$27,921$2,150.26$50,079$8,338.38$22.2KABBV
9$32,597$2,721.06$69,753$14,065.80$37.2KABBV
10$38,346$3,467.67$102,337$24,771.77$64.0KABBV

LPUSF vs ABBV: Complete Analysis 2026

LPUSFStock

Tyman plc supplies engineered fenestration components and access solutions to the construction industry. The company designs and manufactures products that enhance the comfort, sustainability, security, safety, and aesthetics of residential homes and commercial buildings. It operates through three divisions: Tyman North America, Tyman UK & Ireland, and Tyman International. The Tyman North America division manufactures window and door hardware components, extrusions, and sealing systems. It offers single and multipoint locking systems, decorative handle trim sets, and precision rollers; operators, tie bar/locks, and hinges for casement and awning applications; and locks/keepers, integrated tilt latches, rollers, balance systems, seals, and extruded profiles for hung and sliding window applications, as well as a range of specialty access and safety products, including smoke vents, roof access hatches, floor access doors, and ladder posts. The Tyman UK & Ireland division engages in the design, development, manufacture, and distribution of decorative and security hardware and smart ware for residential doors and windows under the ERA and Fab & Fix brands. It also distributes weather seals for residential and commercial fenestration applications, as well as Giesse branded aluminum hardware; and designs and supplies architectural door hardware for commercial applications, as well as offers manufacturing solution for roof, ceiling, wall, and floor access products to the commercial construction industry. The Tyman International division provides hardware and seals to the door and window industry. This segment provides its products under the Schlegel, Giesse, and Reguitti brands. The company was formerly known as Lupus Capital plc and changed its name to Tyman plc in February 2013. Tyman plc was incorporated in 1993 and is headquartered in London, the United Kingdom.

Full LPUSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LPUSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPUSF vs SCHDLPUSF vs JEPILPUSF vs OLPUSF vs KOLPUSF vs MAINLPUSF vs JNJLPUSF vs MRKLPUSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.